Bolt Biotherapeutics (BOLT) Leases (2020 - 2025)
Bolt Biotherapeutics' Leases history spans 6 years, with the latest figure at $19.9 million for Q3 2025.
- For Q3 2025, Leases rose 18.65% year-over-year to $19.9 million; the TTM value through Sep 2025 reached $19.9 million, up 18.65%, while the annual FY2024 figure was $21.8 million, 13.79% up from the prior year.
- Leases for Q3 2025 was $19.9 million at Bolt Biotherapeutics, down from $20.5 million in the prior quarter.
- Across five years, Leases topped out at $24.4 million in Q4 2021 and bottomed at $21000.0 in Q3 2021.
- The 5-year median for Leases is $20.5 million (2025), against an average of $17.5 million.
- The largest annual shift saw Leases skyrocketed 108361.9% in 2022 before it decreased 15.71% in 2024.
- A 5-year view of Leases shows it stood at $24.4 million in 2021, then dropped by 9.71% to $22.1 million in 2022, then dropped by 13.37% to $19.1 million in 2023, then grew by 13.79% to $21.8 million in 2024, then dropped by 8.62% to $19.9 million in 2025.
- Per Business Quant, the three most recent readings for BOLT's Leases are $19.9 million (Q3 2025), $20.5 million (Q2 2025), and $21.1 million (Q1 2025).